Free Papers

Induction of riboflavin-UVA/collagen cross-linking in corneal abscess with different organisms: an experimental study in rabbits

Free Paper Details

First Author: Z.Turkey EGYPT

Co Author(s):    H. Elghonemy   H. Elnashar   S. Negm   H. Elsayed           

Abstract Details

Purpose:

Aim of our study was to evaluate the efficacy of collagen cross-linking as a mono therapy for management of infectious keratitis and to compare the effect of collagen cross-linking therapy on different type of organisms.

Setting:

48 eyes of 24 rabbits, were divided into 4 groups;14 eyes of 7 rabbits in each group except for group D (control group); group A infected with Fusarium, group B: Pseudomonas, group C: Streptococcus, while group D: each rabbit (2 eyes) was injected with either fusarium or pseudomonas or streptococcus.

Methods:

The epithelium was completely scraped off.Rriboflavin photosensitizer solution containing 0.1% riboflavin-5-phosphate in dextran 2o% was dropped onto the cornea before the irradiation and during irradiation. UVA-light (365 nm), intending an irradiance of 3.0 mW/cm2 for 15 minutes in a distance of 45 mm above the cornea.

Results:

Comparison between streptococcus keratitis, Pseudomonas keratitis and Fusarium keratitis regarding the survival of the organism after 4th week following collagen cross-linking(4th stage): There was statistically highly significant difference between the 3 groups. Isolation of Fusarium from the swap samples were no growth in all sample (100%). While isolation of Pseudomonas and streptococcus from the swap samples revealed uncountable growth in all samples (100%).Collagen cross linking (CXL) was done after corneal abscess formation was confirmed then follow-up was performed by corneal scraping was done after CXL at 1, 2, 3 and 4 week for microbial analysis.

Conclusions:

Collagen cross-linking is promising as a mono-therapy and can be an alternative treatment in the management of corneal ulcer caused by Fusarium solani. While it is better be avoided in Streptococcus pneumonia and Pseudomonas aeruginosa as mono-therapy.

Financial Disclosure:

-